Vifor Pharma clinical trials

Acquired by CSL Limited, Aug 9, 2022 · source ↗

The registry lists 26 studies whose lead sponsor is Vifor Pharma. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.

Studies

Recruiting first, then most recently updated. Showing 26 of 26. All CSL Limited studies →

• Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium LevelsRecruitingNCT05766839Phase 2

  Sponsor listed in the registry: Vifor Pharma, Inc. · First submitted after Vifor Pharma, Inc. became part of CSL Limited

• Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital EnvironmentCompletedNCT05514951Not applicable

  Sponsor listed in the registry: Vifor Pharma · First submitted after Vifor Pharma became part of CSL Limited

• FDDA Utilization Study (FDDAU)TerminatedNCT05861492Not applicable

  Sponsor listed in the registry: Vifor Pharma, Inc. · First submitted after Vifor Pharma, Inc. became part of CSL Limited

• Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)CompletedNCT03888066Phase 3

  Sponsor listed in the registry: Vifor Pharma, Inc. · First submitted before Vifor Pharma, Inc. became part of CSL Limited

• Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and HyperkalemiaTerminatedNCT03087058Phase 2

  Sponsor listed in the registry: Vifor Pharma, Inc. · First submitted before Vifor Pharma, Inc. became part of CSL Limited

• Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01100879Phase 4

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)CompletedNCT00520780Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart FailureCompletedNCT01394562Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic DermatitisCompletedNCT03047954Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart FailureTerminatedNCT00821717Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant WomenCompletedNCT01131624Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron DeficiencyCompletedNCT01453608Phase 4

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT00994318Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis PatientsCompletedNCT01324128Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Study of Phosphate Levels in Patients With Chronic Kidney DiseaseCompletedNCT00824460Phase 2

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis PatientsCompletedNCT01464190Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing ChemotherapyCompletedNCT01101399Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-CORCompletedNCT00810030Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Maintenance Treatment of Iron Deficiency in IBD PatientsCompletedNCT00810004Phase 3

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Drug-Drug Interaction Study of Losartan and PA21CompletedNCT01324752Phase 1

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing AgeCompletedNCT01110356Phase 4

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Drug-Drug Interaction Study of Warfarin and PA21CompletedNCT01477424Phase 1

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Drug-Drug Interaction Study of Digoxin and PA21CompletedNCT01477411Phase 1

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Drug-Drug Interaction Study of Omeprazole and PA21CompletedNCT01452906Phase 1

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• A Drug-Drug Interaction Study of Furosemide and PA21CompletedNCT01438359Phase 1

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited

• Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)TerminatedNCT00882414Phase 2

  Sponsor listed in the registry: Vifor Pharma · First submitted before Vifor Pharma became part of CSL Limited